Search
Amyotrophic Lateral Sclerosis Paid Clinical Trials in Maryland
A listing of 8 Amyotrophic Lateral Sclerosis clinical trials in Maryland actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 8 of 8
The state of Maryland currently has 8 active clinical trials seeking participants for Amyotrophic Lateral Sclerosis research studies. These trials are conducted in various cities, including Baltimore, Bethesda, Rockville and Annapolis.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Research Study
Recruiting
Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Sinusitis
Featured Trial
Chronic Cough Clinical Study
Recruiting
We are evaluating an investigational treatment to see if it may help people dealing with chronic cough.
Eligible participants will receive study-related medical care at no cost. You may be compensated for study-related travel and time. Health insurance is not required. If you qualify, you may receive:
Payment up to $1500, which varies by study.
Eligible participants will receive study-related medical care at no cost. You may be compensated for study-related travel and time. Health insurance is not required. If you qualify, you may receive:
Payment up to $1500, which varies by study.
Conditions:
Cough
Chronic Cough
Asthma
Allergic Asthma
Sinusitis
Featured Trial
Healthy Volunteer Trials
Recruiting
Healthy trials near you are looking for participants to help push medical research forward. Click through to learn more!
Conditions:
Healthy
Featured Trial
High blood pressure (Hypertension) Trials
Recruiting
High blood pressure (Hypertension) trials near you are looking for participants to help push medical research forward. Click through to learn more!
Conditions:
High blood pressure (Hypertension)
Featured Trial
Cardiovascular Disease Trials
Recruiting
Cardiovascular Disease trials near you are looking for participants to help push medical research forward. Click through to learn more!
Conditions:
Cardiovascular Disease
Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS
Recruiting
A Phase 2b/3 multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy, safety and tolerability of MN-166 given to ALS participants for 12 months followed by a 6-month open-label extension phase.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
06/19/2024
Locations: Johns Hopkins University, Baltimore, Maryland
Conditions: Amyotrophic Lateral Sclerosis
Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
Recruiting
Background:
Neurodegenerative disorders can lead to problems in movement or memory. Some can cause abnormal proteins to build up in brain cells. Researchers want to understand whether these diseases have related causes or risk factors.
Objective:
To test people with movement or thinking and memory problems to see if they are eligible for research studies.
Eligibility:
People ages 18 and older with a neurodegenerative disorder associated with accumulation of TDP-43 or Tau proteins
Design:... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/11/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Progressive Supranuclear Palsy, Frontotemporal Dementia, Amyotrophic Lateral Sclerosis
A Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation
Recruiting
The primary objective of this study is to evaluate the efficacy of tofersen in presymptomatic adult carriers of a superoxide dismutase 1 (SOD1) mutation with elevated neurofilament (NF). The secondary objectives of this study are to evaluate the safety and tolerability tofersen and to evaluate the effect of tofersen on pharmacodynamics (PD)/treatment response biomarkers when initiated prior to versus at the time of emergence of clinically manifest amyotrophic lateral sclerosis (ALS).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: Johns Hopkins Hospital, Baltimore, Maryland
Conditions: Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation
FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)
Recruiting
The primary purpose of this study is to evaluate the efficacy of ION363 on clinical function and survival in carriers of fused in sarcoma mutations with amyotrophic lateral sclerosis (FUS-ALS).
Gender:
All
Ages:
10 years and above
Trial Updated:
05/30/2024
Locations: Johns Hopkins University, Baltimore, Maryland
Conditions: Amyotrophic Lateral Sclerosis
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
Recruiting
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01 AG045390; funded through 2019) as a single North American research consortium to study FTLD for 2019 and beyond.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/12/2024
Locations: Johns Hopkins University, Baltimore, Maryland +1 locations
Conditions: Frontotemporal Lobar Degeneration (FTLD), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Behavioral Variant Frontotemporal Dementia (bvFTD), Semantic Variant Primary Progressive Aphasia (svPPA), Nonfluent Variant Primary Progressive Aphasia (nfvPPA), FTD With Amyotrophic Lateral Sclerosis (FTD/ALS), Amyotrophic Lateral Sclerosis, Oligosymptomatic PSP (oPSP), C9orf72, GRN Related Frontotemporal Dementia, MAPT Gene Mutation, TBK1 Gene Mutation, Oligosymptomatic Progressive Supranuclear Palsy
Clinical Manifestations and Biomarkers in Amyotrophic Lateral Sclerosis Type 4 and Other Inherited Neurological Disorders of RNA Processing
Recruiting
Background:
Amyotrophic lateral sclerosis type 4 (ALS4) is an inherited motor neuron disease. People with ALS4 have a change in the amount of RNA and DNA that bind together. This binding of RNA with DNA forms units called R-loops. Researchers want to learn how R-loops are related to ALS4. To do this, they will study people with inherited neurological conditions that may affect R-loop levels. These include ALS4, progressive external opthalmoplegia with mitochondrial deletions (PEOB2), Aicardi-Go... Read More
Gender:
All
Ages:
Between 5 years and 120 years
Trial Updated:
02/09/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Amyotrophic Lateral Sclerosis Type 4, Inherited Neurological Disorders of RNA Processing
Investigation on the Cortical Communication (CortiCom) System
Recruiting
The CortiCom system consists of 510(k)-cleared components: platinum PMT subdural cortical electrode grids, a Blackrock Microsystems patient pedestal, and an external NeuroPort Neural Signal Processor. Up to two grids will be implanted in the brain, for a total channel count of up to 128 channels, for six months. In each participant, the grid(s) will be implanted over areas of cortex that encode speech and upper extremity movement.
Gender:
All
Ages:
Between 22 years and 70 years
Trial Updated:
02/07/2024
Locations: Johns Hopkins Medicine, Baltimore, Maryland
Conditions: Tetraplegia, Locked-in Syndrome, Brainstem Stroke, Amyotrophic Lateral Sclerosis
Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients
Recruiting
The objective is to compare the efficacy and safety of masitinib in combination with riluzole versus matched placebo in combination with riluzole for the treatment of Amyotrophic Lateral Sclerosis (ALS).
Gender:
All
Ages:
Between 18 years and 81 years
Trial Updated:
04/14/2023
Locations: Johns Hopkins Medicine Brain Science Institute, Baltimore, Maryland
Conditions: Amyotrophic Lateral Sclerosis
1 - 8 of 8